Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Hospitalization 31% Improvement Relative Risk c19curcumin.com Aldwihi et al. Curcumin for COVID-19 EARLY TREATMENT Favors curcumin Favors control
Aldwihi, 738 patient curcumin early treatment study: 31% lower hospitalization [p=0.1] https://c19p.org/aldwihit
copied to clipboard
Patients’ Behavior Regarding Dietary or Herbal Supplements before and during COVID-19 in Saudi Arabia
Aldwihi et al., International Journal of Environmental Research and Public Health, doi:10.3390/ijerph18105086
11 May 2021    Source   PDF   Share   Tweet
Retrospective survey-based analysis of 738 COVID-19 patients in Saudi Arabia, showing lower hospitalization with vitamin C, turmeric, zinc, and nigella sativa, and higher hospitalization with vitamin D. For vitamin D, most patients continued prophylactic use. For vitamin C, the majority of patients continued prophylactic use. For nigella sativa, the majority of patients started use during infection. Authors do not specify the fraction of prophylactic use for turmeric and zinc.
risk of hospitalization, 31.2% lower, RR 0.69, p = 0.10, treatment 30 of 144 (20.8%), control 207 of 594 (34.8%), NNT 7.1, adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Aldwihi et al., 11 May 2021, retrospective, Saudi Arabia, peer-reviewed, survey, mean age 36.5, 8 authors, study period August 2020 - October 2020.
Contact: oalmohammed@ksu.edu.sa (corresponding author), 436202414@student.ksu.edu.sa, 441204353@student.ksu.edu.sa, yazeed@ksu.edu.sa, alamrif@ksau-hs.edu.sa, afaleh@ksu.edu.sa, ofantoukh@ksu.edu.sa, aasssiri@moh.gov.sa.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCurcuminAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit